The short version

Plain English first. Everything below this section is the same material with the sources, the numbers and the caveats attached.

What KLOW is

A four-component blend. It is our GLOW vial with 10 mg of KPV added — and that one addition is where a third of the interesting questions on this page come from.

Component prices read from our own catalogue on 12 October 2026. The saving is computed, not quoted — if a component price moves, it moves with it.

The composition is not what the label makes it look like

Read the label and you see one big number and three equal small ones. Convert to molecules — which is the level at which a receptor cares — and it goes further out of balance, not less. House arithmetic; every input shown.

The full molar ratio, GHK-Cu : KPV : TB-500 : BPC-157, is 17.7 : 4.1 : 1.6 : 1.0.

Where the component evidence lives

This page does not re-argue the four compounds. Those pages exist: GHK-Cu · BPC-157 · TB-500 · KPV. The question a blend page exists to answer is the one none of them can: what changes because all four are in the same vial?

The copper, which is the thing nobody quantifies

GHK-Cu is not a plain peptide. It is a copper(II) coordination complex, and that turns the shared-vial question from “do these peptides degrade” into “what is the metal doing.”

How much copper is actually in there

One KLOW vial contains 7.91 mg of elemental copper.

For scale, from the NIH Office of Dietary Supplements copper fact sheet:

And now the caveat, which cuts both ways and is the honest part

One widely-read blend guide states that “the copper component is a naturally occurring trace mineral — GHK-Cu doses are well within safe copper exposure ranges.” It gives no milligram figure and names no limit it is claiming to be within. The answer to that is not “false.” The answer is: here is the number — 7.91 mg per vial, 1.98 mg in a single large dose — and you can now compare it to whatever you like.

“The copper is silenced” — the one claim the primary literature contradicts

It is widely repeated that copper's redox activity is silenced when it is complexed by the GHK tripeptide, which is offered as proof that a copper peptide is inert in a shared vial. The complexation is real — binding constant log K = 16.44, higher than albumin's 16.2, so the copper is held tightly and is not simply free copper in solution.

What that does and does not license:

• Publishable: the GHK–Cu complex is substantially less redox-active than free copper, but it is not redox-silent, and it still generates ROS in solution even with excess ligand present.
• Publishable: the vendor formulation of this point overstates what the primary literature supports.
• Not publishable, and we will not imply it: that this degrades the other three peptides in a KLOW vial. Nobody has measured that. The mechanism is available; the measurement is not.

Competitive chelation, raised and left open

House reasoning, flagged as such. BPC-157 has a free N-terminal amino group and three carboxylate side chains; KPV has a free N-terminal lysine with two amino groups. In principle those can coordinate copper. In practice GHK's binding constant is high enough to exceed albumin's, so copper transfer to a competing peptide in the vial is thermodynamically unfavourable and the metal should stay put.

We could not find this measured for any of these peptides. The claim we are entitled to make is the conditional one: the chelation chemistry predicts the copper stays on GHK, nobody has checked, and the paper above shows the complex is not as inert as it is usually described.

What our paperwork does and does not cover

This is the section where a page like this normally goes quiet. We are going to write it anyway, because the position is awkward and you should have it.

What we do hold, and why it is genuinely informative

KLOW is GLOW plus KPV, and GLOW is certified. Three of KLOW's four components sit in a GLOW vial at exactly the same masses — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg. So the GLOW certificate is direct evidence about three-quarters of this product, and it is more interesting than a purity number:

Three things follow, and we will take them in order of how much they help us.

• It resolves all three analytes separately, and 61.84 + 11.41 + 12.12 = 85.37 closes exactly against the stated total. That is what a blend certificate has to do and it is not what every blend certificate does. On a single compound, “99.9% pure” means one peak, one identity, one number. On a four-component vial, purity of what? A blend certificate must resolve analytes spanning 342 to 1,420 daltons, one of which is a metal complex that behaves differently on reversed-phase HPLC from a plain peptide — and it must establish that the ratio is right, which a purity figure does not address at all.
• The vial is 22% over its nominal fill. Overfill, not underfill — but it is not uniform across the three components, so “they just filled it generously” is a description rather than an explanation.
• The copper number moves with it. 61.84 mg of GHK-Cu is 9.78 mg of elemental copper in a GLOW vial, against the 7.91 mg the label arithmetic predicts. If a KLOW vial is filled the same way, the vial figure on this page is a floor rather than a ceiling.

The blue powder, and the one check a buyer can actually run

GHK-Cu is naturally blue, and it is the only chromophore among the four — the other three are colourless in solution. So a correctly compounded KLOW should be visibly blue, and our GLOW certificate independently records the appearance as “blue powder.” A vial of this kind that reconstitutes water-clear is telling you something, and it is close to the only component-level check available to anyone without a mass spectrometer.

Two limits, because the check is weaker than it looks. Colour confirms copper is present. It does not confirm the copper is at 50 mg, does not confirm it is complexed to GHK rather than sitting there as a copper salt, and says nothing whatsoever about the other three components. And the observation above is from the GLOW certificate; we have not reconstituted a KLOW vial and photographed it.

Why a certificate matters more on a blend than on a single compound

Three things compound. Four chances to be wrong instead of one — a vial can be short or substituted on any single component and still weigh correctly and still look correct. A blend certificate is a harder document, as above. And the buyer has no route to attribution: with four compounds in one solution, a reaction, a non-response or a wrong vial cannot be traced to a component.

Laid over all of it is FDA's own finding from July 2026 that for these substances “it is unclear, chemically, what these peptides even are” and there is “no universally accepted chemical formula for each compound.” A blend multiplies an identity problem the regulator could not solve for one compound at a time.

Has this combination ever been studied?

No. And we went looking properly, so here is exactly what “no” covers.

The single exception is a 2021 retrospective chart review in which four people received BPC-157 and thymosin β-4 — as two separate intra-articular injections into a knee, not as a blend — and the combination arm did numerically worse than the BPC-157-alone arm (75% against 91.6%). It is set out in full on the Wolverine page, because it bears on that product directly.

The rationale, stated fairly and then classified

The story is that the four map onto sequential phases of healing — GHK-Cu for remodelling and collagen, BPC-157 for angiogenic signalling, TB-500 for cell migration, KPV for inflammation. Be fair about it: each compound does have a preclinical literature pointing at a different node, and a pharmacologist asked to design a repair combination would not laugh at that list.

And be exact about what it is. Synergy is a technical claim with a technical test: an arm for each compound alone, an arm for the combination, and a comparison against an additivity model. No such experiment exists for any pair among these four. The claim is a hypothesis about why a combination might work. That is a legitimate thing to have. It is not a finding, and it is uniformly delivered as though it were one — on pages that otherwise attach a PMID to every single-compound claim.

An honest limit on our negative. PubMed and PubMed Central served CAPTCHA challenges throughout this research pass and the literature APIs were unreachable from our connection, so these searches ran across scholarly websites rather than as database queries. That is a weaker instrument for proving an absence. Read it as “we searched hard and found nothing” rather than as a proof.

The shared-vial problem

One vial means one of everything — one reconstitution volume, one concentration, one diluent, one storage temperature, one in-use clock, one dose schedule, one injection site, one lot, one certificate. Any respect in which four components would want different handling is a respect in which at least three of them are being handled wrongly.

Do the four have different stability profiles in solution?

Nobody knows, because the individual studies mostly do not exist either. Here is the whole of what we could source:

• GHK-Cu: a compounding-pharmacy source states it is stable in water between pH 4.5–7.4 at 60 °C for at least two weeks, with solubility up to 325 mg/mL. The underlying study is not named on that page and we could not trace it — treat it as compounding convention with an unverified source, not as data we have read.
• BPC-157, TB-500 and KPV: no aqueous stability study located for any of the three. FDA's briefing documents for BPC-157 and KPV both identify missing impurity, aggregate and microbiological data as a reason the substances are not well characterised.

So the comparison cannot be made from published data, and that is the finding: we went looking for four stability profiles to set against each other, and there are three we could not find and one we could not verify.

The oxidation argument, and credit where it is due

The most technically serious defence of blending copper with peptides argues that “none of the peptides in this combination contain cysteine or methionine residues — the primary targets of copper-catalyzed oxidation — making the most concerning degradation pathway chemically impossible.” Checked residue by residue against the published sequences, on its narrow terms it is correct, and we would rather say so than dismiss a good argument:

Three qualifications, all of which belong here rather than in a footnote:

1. It holds for TB-500 as the derivative it is. TB-500 is the Ac-LKKTETQ fragment and contains no methionine, so the argument stands. Full-length thymosin β-4 does contain one — so a vial shipped with the full-length protein under the TB-500 name would break the argument. That is a labelling failure to watch for, not an ambiguity in what TB-500 means.
2. No cysteine and no methionine rules out one pathway, not the category. House reasoning, flagged: metal-catalysed oxidation is not restricted to sulfur-containing residues — histidine, lysine, proline and arginine side chains and the backbone itself are documented substrates in the general protein-chemistry literature. GHK's own histidine is a target, BPC-157 is 5/15 proline, and TB-500 is 3/7 lysine. We have not sourced a study of metal-catalysed oxidation in these specific peptides and will not imply we have.
3. The same article's copper claim is the one contradicted above. And to its credit, it concedes in its own words: “No peer-reviewed clinical trials have established the safety or efficacy of this specific combination in humans.”

The in-use clock

Our house convention is 28 days refrigerated after reconstitution, and our own storage guide already says what that is: “Convention, not a stability study” — a handling rule “repeated as though it were data.”

Three things you give up, which the $108 is the price of

You cannot stop one and continue another. Want the repair components without the copper? A blend cannot do that. Want to run one for eight weeks and another for four? It cannot do that either. A blend is a commitment to all four components, at a fixed ratio, for the same duration.

You cannot attribute a reaction. Four candidate causes plus the diluent, one solution, no way from the outside to tell which. Someone who has run each component separately knows what they tolerate; someone whose first exposure to all four is a single KLOW injection does not.

And you cannot titrate. Which is the next section, and it is the sharpest one.

Reconstitution

80 mg is a lot of solid for a small vial, and the volume you choose sets four concentrations at once.

At 3 mL, on a U-100 insulin syringe:

House arithmetic from the label fill. Note the copper column: a 75-unit draw carries more than twice an adult's entire daily copper requirement in one injection. And if a KLOW vial is filled like our certified GLOW vial — GHK-Cu 23.7% over label — every figure in that column is about a quarter higher again. Our reconstitution calculator will run whatever volume you actually use.

Four components, four conventions, one syringe

This is the finding. At most one of them can be right.

Work it three ways at 3 mL. House arithmetic throughout.

The 28-day clock, and the proportional discard

Whatever the schedule, if the vial outlasts 28 days the remainder is discarded — and in a blend the discard is proportional across all four components simultaneously. You cannot rebalance by taking less of one and more of another. That is our existing 28-day rule argument, and it bites hardest on the biggest vial on the shelf.

What the $30 over GLOW actually buys

KLOW is GLOW plus 10 mg of KPV: $100 becomes $130. It is worth saying exactly what that is.

And the counter-argument, because it is a real one

Two things cut the other way and we would rather print them than be accused of only arguing one side. KPV is not a trace addition — it is 17.0% of the molecules in the vial despite being 12.5% of the mass, because a tripeptide gives you far more molecules per milligram than a 15-mer. And $30 is a normal price for that delta: an eleven-vendor Canadian sweep put the KPV premium band at $10–25 with a median of $20, so $30 is at the top of the range but not outside it.

The point is not that the price is wrong. The point is that a page should say what the buyer is buying, and the answer here is: more molecules of the least-evidenced compound on the shelf. That is a legitimate thing to buy if you know it is what you are buying.

The PCAC panel recommended KPV for the 503A compounding list anyway, 8–6 with one abstention — against the recommendation of the FDA reviewers who wrote the paragraph above. Both facts are true and belong together.

Storage

Lyophilised: −20 °C, sealed, dark, desiccated, for long-term storage; refrigerated for shorter periods. This is the one handling question where the shared vial costs nothing — all four powders want the same conditions.

Reconstituted: 2–8 °C, in the dark. The 28 days is a convention, not a stability study, and for this vial it is standing in for more missing data than anywhere else in the catalogue.

Copper-specific note, and it is chemistry rather than a warning: GHK-Cu is a redox-active complex, so light and air are less trivial for this vial than for a plain peptide, and strong oxidising agents are an obvious incompatibility. Let the vial reach room temperature before breaking the seal, and add diluent down the side of the glass rather than onto the cake.

Frequency, cycle length and washout

This page carried no cycling guidance until 7 October 2026. That was an omission rather than a position, and it is worth saying plainly: if you read this page before today and concluded that KLOW does not need a washout while GLOW does, that was our fault, not a difference between the products.

Carried over from how GHK-Cu is used on its own. These are reported conventions, not a recommendation, and not a schedule anybody has tested on this blend.

The vial and the window bind in opposite directions, and which one bites depends on the draw

At 3 mL a KLOW vial holds 300 units, and we recommend 28 days for a vial once it has been reconstituted. Those two limits do not agree with each other, and which one you hit first changes with the size of the draw:

GLOW sits the other way round — its own page notes that a 70 mg vial at the lower end of the reported range outlasts the window. On KLOW the heavier draws invert it. Worth working out before you mix, because the two situations call for different planning: one wastes days, the other wastes material.

What the cycle is, and what it is not

None of this is a recommendation, a protocol, or advice on use. It is a record of what is conventionally reported and of the arithmetic of the vial. Decisions about whether to use this at all, and in what amount, belong to you and a qualified clinician who has assessed you.

Reported effects

There is no safety dataset for this combination, and there is no adverse-event surveillance that would produce one. Here is what does exist.

The one authority that addresses blends directly

Stated because we must: that page contains no case data, no call-volume statistics and no adverse-event numbers. It is a poison centre's clinical judgement about a practice, not a report of harms observed.

Adverse-event reports involving blends

We searched for case reports, adverse event reports and pharmacovigilance signals naming a peptide blend, a peptide stack, or any of these products. We found none.

Immunogenicity and aggregation, from the regulator

FDA's July 2026 briefing documents name a risk that scales with a blend rather than away from one. On BPC-157: “we cannot rule out the potential for immunogenicity associated with these impurities and peptide-related aggregates,” and given parenterally it “may pose a significant risk for immunogenicity, potentially amplified by aggregation.” On KPV the agency notes peptides can trigger “life-threatening and catastrophic reactions” and have an “inherent tendency to aggregate.”

A shared vial is a shared solution, aggregation is a solution-phase problem, and nobody has measured it for this mixture.

Copper, honestly

The copper arithmetic above is not a claim of harm. There is no established parenteral limit to say 7.91 mg exceeds, and we are not going to invent one. What we will say is that the figure is not small against every oral reference point that exists, that injection bypasses the regulation the gut applies, that the complex is less redox-active than free copper but not silent, and that no long-term human safety data exists for injected GHK-Cu at any dose. No human trial of injected GHK-Cu was located at all; the substantive literature on this compound is topical and cosmetic.

Regulatory status

This is the strongest single statement on the page, and it needs no qualification at all.

Canada

From the 9 April 2026 advisory, verbatim: these products are “illegal in Canada and have not been assessed for safety, efficacy, and quality by Health Canada”; “In Canada, peptides are generally regulated as prescription drugs”; and on research-use-only labelling, explicitly: “This type of labelling does not make these products legal or exempt from regulatory requirements.”

The United States, and what the July 2026 votes were not

Three of the four went before FDA's Pharmacy Compounding Advisory Committee on 23 July 2026, each with its own briefing document, each recommended for the 503A bulk substances list by 8–6 with one abstention. GHK-Cu was not heard at all. Three things belong together:

• FDA's own scientists opposed all seven substances heard — the briefing materials found the available studies “short in duration, small in sample size, and insufficient to establish safety or effectiveness.” The panel voted the other way by one or two votes.
• A PCAC vote is an advisory recommendation about compounding-pharmacy bulk sourcing in the United States. It is not an approval, and formal rulemaking has not happened.
• It has no effect in Canada whatsoever.

A correction we have made in-house and will not repeat: none of the four is on FDA's Category 2 “do not compound” list. All four appear on the separate “nominated but withdrawn” list. Those are different documents and they get conflated in both directions.

Anti-doping, and a distinction worth keeping

BPC-157 and TB-500 are named on the 2026 prohibited list. GHK-Cu and KPV are not named anywhere on it — they are prohibited because the catch-all section sweeps up any pharmacological substance with no regulatory approval for human therapeutic use, and neither has such approval. The practical status is identical — prohibited at all times, in and out of competition — but being named and being captured are different things, and a page that blurs them is wrong.

Has any regulator addressed a blend as a blend?

We checked Health Canada advisories and recalls, FDA warning letters, the FDA compounding lists, the July 2026 PCAC agenda and the 2026 anti-doping list. Every one of them addresses substances. None names a multi-peptide product. The July 2026 committee heard seven single substances, each with its own briefing document and its own proposed indication: a combination was never before the committee.

Sentient Biogenix supplies this product for laboratory research use only. It is not for human or veterinary use.

Questions we actually get

Is KLOW just GLOW with something extra?

Yes — GLOW plus 10 mg of KPV, $100 to $130. KPV is the component with the least evidence behind it of the four; FDA's July 2026 review of it says “No human studies were identified.” It is 17% of the molecules in the vial, so it is not a token addition, and $30 is a normal market price for that delta. Just know what you are buying.

How much copper is in it?

7.91 mg of elemental copper per vial by label arithmetic — 8.8 times the adult oral RDA. Our certified GLOW vial came in with GHK-Cu 23.7% above label, which would put a similarly-filled KLOW nearer 9.8 mg. A large single draw carries about 2 mg of copper.

Is that dangerous?

We do not know, and neither does anyone else, and that is the honest answer. The published copper limits are oral limits and the gut regulates how much it lets through; an injection does not go through the gut. There is no established parenteral upper limit for copper. So the reassuring comparison and the alarming one are both unavailable. What is left is that nobody has set a number for this route.

Doesn't the tripeptide make the copper inert?

Less reactive, not inert. The primary literature reports the GHK–Cu complex “does still form ROS in solution”, and that excess ligand did not prevent it. The vendor version of this — that copper is “silenced” — overstates the source it rests on.

Does the copper damage the other peptides in the vial?

Nobody has measured it. None of the four peptides contains cysteine or methionine, which genuinely does rule out the best-known copper-catalysed oxidation route — that argument is correct and we will not pretend otherwise. But it rules out one pathway, not the category. And it holds for TB-500 as the 889-dalton derivative it is — full-length thymosin β-4 does contain a methionine, so a vial mislabelled that way would break it.

Should it be blue?

Yes. GHK-Cu is blue and it is the only coloured component; our GLOW certificate records the powder as “blue powder.” A vial of this kind that reconstitutes water-clear is telling you something. But colour only confirms copper is present — not how much, not that it is complexed to GHK, and nothing at all about the other three components.

Does KLOW have a certificate?

Not at present. We checked the register rather than guessing. What we do hold is the GLOW certificate, which covers three of the four components at identical masses and itemises each one separately — that is set out above, including the part where the measured masses run 14 to 24% above label.

Has this combination been studied?

No. No study has given GHK-Cu or KPV alongside any of the others, in any species. No study has given all four. And there is no study of any kind of a premixed multi-peptide solution. The only adjacent human data is one uncontrolled chart review in which four people got BPC-157 and thymosin β-4 as two separate injections, and the combination arm did worse.

How much water?

3 mL, which puts it at 26.7 mg/mL and matches the concentration band of our GLOW vial. 2 mL works chemically but makes this the most concentrated blend on the shelf, which is the opposite of what 80 mg argues for.

So why do you sell it?

Because it is a legitimate research combination and it is $108 cheaper than its parts. What we will not do is tell you the four work better together, because nobody has tested whether any two of them do — and we would rather you bought this knowing that than found out later.

References

1. Min J-H, Sarlus H, Harris RA. Glycyl-L-histidyl-L-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro. Metallomics 2024;16(5):mfae019. DOI 10.1093/mtomcs/mfae019. PMID 38599632. academic.oup.com — the source of “does still form ROS in solution.” Read in full.
2. NIH Office of Dietary Supplements. Copper — fact sheet for health professionals. ods.od.nih.gov — the RDA, the upper limit, average intake, and the statement that the limits do not address supervised or non-oral routes.
3. US Food and Drug Administration. Briefing document, KPV, Pharmacy Compounding Advisory Committee, 23–24 July 2026. fda.gov — “No human studies were identified.”
4. US Food and Drug Administration. Briefing document, BPC-157, same committee. fda.gov — the “not well-characterized” finding and the immunogenicity language.
5. Steinzor P. FDA panel backs 6 peptides for compounding. AJMC, 3 September 2026. ajmc.com — vote counts, and “FDA scientists uniformly opposed adding any of the 7 substances.” Corroborated by Pharmaceutical Executive, 24 July 2026, which also carries the “What is it?” quotation.
6. Health Canada. Think twice before injecting peptides bought online. Public advisory, 9 April 2026. recalls-rappels.canada.ca — names all four components. Read directly in-house on 29 August 2026; the host blocks automated fetching.
7. Health Canada. Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks. Public advisory, 1 August 2025 — 44 substances; BPC-157, GHK-Cu (and GHK and Pal-GHK separately) and Thymosin-β4 named; KPV not named; no blends.
8. Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics 2015;2(3):236–247. DOI 10.3390/cosmetics2030236 — the substantive GHK-Cu literature, which is topical and cosmetic.
9. Fagron Academy. Copper peptide (GHK-Cu): clinical uses, stability and compounding tips. fagronacademy.us — the pH 4.5–7.4 stability figure and the blue colour. The underlying stability study is not named and we could not trace it.
10. Missouri Poison Center. Is peptide stacking dangerous? The risks of unregulated injections. 11 May 2026. missouripoisoncenter.org — clinical judgement about the practice; contains no case data.
11. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine 2021;27(4):8–13. PMID 34324435 — the only co-administration study touching any of these compounds. Set out in full on the Wolverine page.
12. Sentient Biogenix certificate RB-GLOW-70-050126 (GLOW 70 mg), Testides, tested 9 May 2026. Certificate register. No certificate is currently on file for KLOW 80 mg.

What we could not check, listed rather than hidden. PubMed and PubMed Central were CAPTCHA-blocked throughout this research pass and the literature APIs were unreachable from our connection, so the combination searches ran across scholarly websites rather than as database queries — a weaker instrument for proving a negative. We could not open the primary KPV preclinical paper (PMID 18092346), the Esposito 2012 characterisation of what is in a TB-500 vial, a 2026 narrative review of BPC-157, or a peer-reviewed netnography of how these compounds are actually used, which would have let the dose conventions cite a study instead of vendor pages. The GHK-Cu stability figure rests on a compounding-pharmacy page that does not name its source. The GHK-Cu molecular weight of 401.914 is our own computation from the published formula, since the reference we used gives the formula but no weight; the copper figures throughout follow from it. And the anti-doping list was read through a third-party reproduction because the official host blocks automated fetching.